EPIC SCIENCES RAISES $43M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS

Funding will accelerate commercial launch of DefineMBC™ and expand Epic Sciences’ liquid biopsy solutions for key global oncology trials SAN DIEGO, June 2, 2022 /PRNewswire/ — Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $43…

Click here to view original post